DGX up +1.12% percent right now. $DGX High is at 63.54 and the Low 62.84 with current volume of 578,329.
Recent News posted below.
DGX Quest Diagnostics Inc Recent Headline News
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 62.86 (+0.17), LH: 100.02 (-0.96), ILMN: 188.03 (-0.24), PKI: 43.94 (-0.08)
SmarTrend Watching for Potential Pullback in Shares of Quest Diagnostics After 1.62% Gain
Comtex SmarTrend(R) - Mon Nov 10, 5:11PM CST
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $61.62 to a high of $63.06. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $62.87 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DGX: 62.86 (+0.17)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Quest Diagnostics Is Down 1.9% (DGX)
Comtex SmarTrend(R) - Mon Nov 10, 11:21AM CST
When Quest Diagnostics (NYSE GX) reported earnings 18 days ago on October 23rd, 2014, analysts, on average, expected the company to report earnings of $1.07 on sales of $1.9 billion. The company actually reported EPS of $1.10 on sales of $1.9 billion, beating EPS estimates by $0.03 and beating revenue estimates by $32.2 million. Since the company's report, shares of Quest Diagnostics have fallen from $62.88 to $61.69, representing a loss of 1.9% in the past 18 days.
DGX: 62.86 (+0.17)
Technical Updates, Quarterly Earnings, Legislated Requirements, Lawsuit Dismissal, and Revised Operational Structure - Research Reports on United Rentals, Lilly, Quest Diagnostics, Agilent and GE
PR Newswire - Thu Nov 06, 7:40AM CST
Today, Analysts Review released its research reports regarding United Rentals, Inc. (NYSE: URI), Eli Lilly and Company (NYSE: LLY), Quest Diagnostics Inc. (NYSE: DGX), Agilent Technologies Inc. (NYSE: A) and General Electric Company (NYSE: GE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7739-100free.
GE: 26.33 (-0.14), A: 41.74 (+0.21), DGX: 62.86 (+0.17), LLY: 68.07 (-0.28), URI: 113.56 (-0.14)
Quest Diagnostics (DGX): Stock With Unusual Social Activity
at The Street - Wed Nov 05, 9:35AM CST
Trade-Ideas LLC identified Quest Diagnostics (DGX) as an unusual social activity candidate
DGX: 62.86 (+0.17)
Quest Diagnostics Discusses Progress in Executing Strategy to Drive Shareholder Value and Presents Outlook at Investor Day
PR Newswire - Wed Nov 05, 7:00AM CST
At a meeting with analysts and investors at its Investor Day here today, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, plan to discuss the company's industry leadership position and the progress made in executing its strategy to drive shareholder value. A live webcast of the meeting will be broadcast simultaneously beginning at 9 am ET.
DGX: 62.86 (+0.17)
NYSE stocks posting largest volume increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
RCAP: 11.10 (+0.43), LVLT: 46.55 (+0.26), BRP: 23.55 (+0.21), DGX: 62.86 (+0.17), JBL: 21.11 (+0.08), UBA: 22.10 (-0.15), DOV: 80.72 (-0.67), AP: 19.23 (-0.22), UBP: 18.65 (-0.01), KAMN: 40.95 (-0.49), CVD: 100.47 (-0.40)
After Yesterday's Decline of 1.21%, Quest Diagnostics Offers Investors Better Value
Comtex SmarTrend(R) - Tue Nov 04, 4:03PM CST
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $59.25 to a high of $61.72. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $61.61 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DGX: 62.86 (+0.17)
Quest Diagnostics Introduces BRCAvantage Plus(TM), Providing New Choices in Genetic Breast Cancer Risk Testing
PR Newswire - Tue Nov 04, 11:50AM CST
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced BRCAvantage Plus, the company's first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states.
DGX: 62.86 (+0.17)
Watch for Shares of Quest Diagnostics (DGX) to Approach Support at $60.50
Comtex SmarTrend(R) - Tue Nov 04, 9:37AM CST
Shares of Quest Diagnostics (NYSE GX) opened today below their pivot of $62.41 and have already reached the first level of support at $61.31. Should the shares continue to fall, the support pivots of $60.50 and $58.59 will be of interest.
DGX: 62.86 (+0.17)
5 Hated Short-Squeeze Stocks That You Should Love
at The Street - Tue Nov 04, 5:00AM CST
These heavily shorted stocks could get squeezed much higher on any positive catalyst.
EXC: 37.61 (+0.01), DGX: 62.86 (+0.17), MTB: 124.74 (+0.08), O: 46.87 (-0.23), ADT: 35.49 (-1.35)
LabCorp Diversifies With $6.1 billion Covance Buyout
at Investor's Business Daily - Mon Nov 03, 11:08AM CST
Diagnostics giant Laboratory Corp. of America (LH) agreed to a $6.1 billion cash-and-stock deal to acquire contract research organization Covance (CVD), or about 105.12 per Covance share, 32% above its closing price Friday. The news sent Covance...
DGX: 62.86 (+0.17), LH: 100.02 (-0.96), CVD: 100.47 (-0.40)
Health Care Services Stocks Highlight - Express Scripts Holding, Omnicare, MEDNAX, DaVita HealthCare Partners, and Quest Diagnostics
PR Newswire - Wed Oct 29, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Express Scripts Holding Co. (NASDAQ: ESRX), Omnicare Inc. (NYSE: OCR), MEDNAX Inc. (NYSE: MD), DaVita HealthCare Partners Inc. (NYSE: DVA), and Quest Diagnostics Inc. (NYSE: DGX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, October 28, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,005.75, up 1.12% and the NASDAQ Composite closed at 4,564.29, up 1.75%. The S&P 500 finished the session 1.19% higher at 1,985.05. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
OCR: 69.03 (+0.30), ESRX: 77.73 (-0.26), DVA: 75.89 (+1.17), DGX: 62.86 (+0.17), MD: 62.46 (+0.08)
LabCorp Outshines Earnings, Revenues in Q3; Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:30PM CDT
Laboratory Corporation of America Holdings (LH) reported third-quarter 2014 adjusted earnings per share (EPS) of $1.80.
CAH: 79.63 (+0.54), DGX: 62.86 (+0.17), LH: 100.02 (-0.96), HSIC: 129.21 (-0.41)
Comparing America's 3 Largest Medical Laboratories And Research Companies
Joseph Cafariello - at Seeking Alpha - Tue Oct 28, 7:27AM CDT
TMO: 118.00 (+1.15), A: 41.74 (+0.21), DGX: 62.86 (+0.17)
6 Fairly Valued Companies Worthy Of Further Research This Week
Benjamin Clark - at Seeking Alpha - Mon Oct 27, 4:33PM CDT
ROP: 157.10 (-1.43), DGX: 62.86 (+0.17), MOS: 44.78 (+0.67), LLY: 68.06 (-0.29), JNPR: 20.53 (-0.97), HUM: 136.50 (+4.04)
Quest Diagnostics' (DGX) CEO Stephen Rusckowski on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 5:45PM CDT
DGX: 62.86 (+0.17)
Quest Diagnostics Beats on Earnings & Revs, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 12:15PM CDT
Quest Diagnostics' (DGX) third-quarter 2014 adjusted earnings per share (EPS) from continuing operations came in at $1.10.
DGX: 62.86 (+0.17), AMED: 25.22 (+0.08), HLS: 39.05 (-0.06), GTIV: 19.43 (-0.23)
Recent News posted below.
DGX Quest Diagnostics Inc Recent Headline News
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 62.86 (+0.17), LH: 100.02 (-0.96), ILMN: 188.03 (-0.24), PKI: 43.94 (-0.08)
SmarTrend Watching for Potential Pullback in Shares of Quest Diagnostics After 1.62% Gain
Comtex SmarTrend(R) - Mon Nov 10, 5:11PM CST
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $61.62 to a high of $63.06. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $62.87 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DGX: 62.86 (+0.17)
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Quest Diagnostics Is Down 1.9% (DGX)
Comtex SmarTrend(R) - Mon Nov 10, 11:21AM CST
When Quest Diagnostics (NYSE
GX) reported earnings 18 days ago on October 23rd, 2014, analysts, on average, expected the company to report earnings of $1.07 on sales of $1.9 billion. The company actually reported EPS of $1.10 on sales of $1.9 billion, beating EPS estimates by $0.03 and beating revenue estimates by $32.2 million. Since the company's report, shares of Quest Diagnostics have fallen from $62.88 to $61.69, representing a loss of 1.9% in the past 18 days. DGX: 62.86 (+0.17)
Technical Updates, Quarterly Earnings, Legislated Requirements, Lawsuit Dismissal, and Revised Operational Structure - Research Reports on United Rentals, Lilly, Quest Diagnostics, Agilent and GE
PR Newswire - Thu Nov 06, 7:40AM CST
Today, Analysts Review released its research reports regarding United Rentals, Inc. (NYSE: URI), Eli Lilly and Company (NYSE: LLY), Quest Diagnostics Inc. (NYSE: DGX), Agilent Technologies Inc. (NYSE: A) and General Electric Company (NYSE: GE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7739-100free.
GE: 26.33 (-0.14), A: 41.74 (+0.21), DGX: 62.86 (+0.17), LLY: 68.07 (-0.28), URI: 113.56 (-0.14)
Quest Diagnostics (DGX): Stock With Unusual Social Activity
at The Street - Wed Nov 05, 9:35AM CST
Trade-Ideas LLC identified Quest Diagnostics (DGX) as an unusual social activity candidate
DGX: 62.86 (+0.17)
Quest Diagnostics Discusses Progress in Executing Strategy to Drive Shareholder Value and Presents Outlook at Investor Day
PR Newswire - Wed Nov 05, 7:00AM CST
At a meeting with analysts and investors at its Investor Day here today, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, plan to discuss the company's industry leadership position and the progress made in executing its strategy to drive shareholder value. A live webcast of the meeting will be broadcast simultaneously beginning at 9 am ET.
DGX: 62.86 (+0.17)
NYSE stocks posting largest volume increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
RCAP: 11.10 (+0.43), LVLT: 46.55 (+0.26), BRP: 23.55 (+0.21), DGX: 62.86 (+0.17), JBL: 21.11 (+0.08), UBA: 22.10 (-0.15), DOV: 80.72 (-0.67), AP: 19.23 (-0.22), UBP: 18.65 (-0.01), KAMN: 40.95 (-0.49), CVD: 100.47 (-0.40)
After Yesterday's Decline of 1.21%, Quest Diagnostics Offers Investors Better Value
Comtex SmarTrend(R) - Tue Nov 04, 4:03PM CST
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $59.25 to a high of $61.72. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $61.61 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. DGX: 62.86 (+0.17)
Quest Diagnostics Introduces BRCAvantage Plus(TM), Providing New Choices in Genetic Breast Cancer Risk Testing
PR Newswire - Tue Nov 04, 11:50AM CST
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced BRCAvantage Plus, the company's first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states.
DGX: 62.86 (+0.17)
Watch for Shares of Quest Diagnostics (DGX) to Approach Support at $60.50
Comtex SmarTrend(R) - Tue Nov 04, 9:37AM CST
Shares of Quest Diagnostics (NYSE
GX) opened today below their pivot of $62.41 and have already reached the first level of support at $61.31. Should the shares continue to fall, the support pivots of $60.50 and $58.59 will be of interest. DGX: 62.86 (+0.17)
5 Hated Short-Squeeze Stocks That You Should Love
at The Street - Tue Nov 04, 5:00AM CST
These heavily shorted stocks could get squeezed much higher on any positive catalyst.
EXC: 37.61 (+0.01), DGX: 62.86 (+0.17), MTB: 124.74 (+0.08), O: 46.87 (-0.23), ADT: 35.49 (-1.35)
LabCorp Diversifies With $6.1 billion Covance Buyout
at Investor's Business Daily - Mon Nov 03, 11:08AM CST
Diagnostics giant Laboratory Corp. of America (LH) agreed to a $6.1 billion cash-and-stock deal to acquire contract research organization Covance (CVD), or about 105.12 per Covance share, 32% above its closing price Friday. The news sent Covance...
DGX: 62.86 (+0.17), LH: 100.02 (-0.96), CVD: 100.47 (-0.40)
Health Care Services Stocks Highlight - Express Scripts Holding, Omnicare, MEDNAX, DaVita HealthCare Partners, and Quest Diagnostics
PR Newswire - Wed Oct 29, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Express Scripts Holding Co. (NASDAQ: ESRX), Omnicare Inc. (NYSE: OCR), MEDNAX Inc. (NYSE: MD), DaVita HealthCare Partners Inc. (NYSE: DVA), and Quest Diagnostics Inc. (NYSE: DGX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, October 28, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,005.75, up 1.12% and the NASDAQ Composite closed at 4,564.29, up 1.75%. The S&P 500 finished the session 1.19% higher at 1,985.05. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
OCR: 69.03 (+0.30), ESRX: 77.73 (-0.26), DVA: 75.89 (+1.17), DGX: 62.86 (+0.17), MD: 62.46 (+0.08)
LabCorp Outshines Earnings, Revenues in Q3; Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:30PM CDT
Laboratory Corporation of America Holdings (LH) reported third-quarter 2014 adjusted earnings per share (EPS) of $1.80.
CAH: 79.63 (+0.54), DGX: 62.86 (+0.17), LH: 100.02 (-0.96), HSIC: 129.21 (-0.41)
Comparing America's 3 Largest Medical Laboratories And Research Companies
Joseph Cafariello - at Seeking Alpha - Tue Oct 28, 7:27AM CDT
TMO: 118.00 (+1.15), A: 41.74 (+0.21), DGX: 62.86 (+0.17)
6 Fairly Valued Companies Worthy Of Further Research This Week
Benjamin Clark - at Seeking Alpha - Mon Oct 27, 4:33PM CDT
ROP: 157.10 (-1.43), DGX: 62.86 (+0.17), MOS: 44.78 (+0.67), LLY: 68.06 (-0.29), JNPR: 20.53 (-0.97), HUM: 136.50 (+4.04)
Quest Diagnostics' (DGX) CEO Stephen Rusckowski on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 5:45PM CDT
DGX: 62.86 (+0.17)
Quest Diagnostics Beats on Earnings & Revs, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 12:15PM CDT
Quest Diagnostics' (DGX) third-quarter 2014 adjusted earnings per share (EPS) from continuing operations came in at $1.10.
DGX: 62.86 (+0.17), AMED: 25.22 (+0.08), HLS: 39.05 (-0.06), GTIV: 19.43 (-0.23)
